ストックスクリーナーアプリを入手
14.55
0.55%
-0.08
Enanta Pharmaceuticals Inc (ENTA) 最新ニュース
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Above 50-Day Moving AverageHere's Why - MarketBeat
Enanta (ENTA) Begins Phase 1 Trial for EDP-978 - GuruFocus
Enanta doses first patient in phase 1 trial of urticaria drug - Investing.com Australia
Gains Report: Should I trade or invest in Enanta Pharmaceuticals IncEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria - BioSpace
Enanta Pharmaceuticals Initiates Phase 1 Trial of EDP-978 in Chronic Urticaria - marketscreener.com
Meme Stocks: Does Enanta Pharmaceuticals Inc have strong fundamentals2026 Big Picture & Weekly Setup with High ROI Potential - baoquankhu1.vn
ENTA Stock Price, Quote & Chart | ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) - ChartMill
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in - PharmiWeb.com
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 - Business Wire
Trading Systems Reacting to (ENTA) Volatility - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving AverageShould You Sell? - MarketBeat
Jefferies reiterates Enanta Pharmaceuticals stock rating on patent case By Investing.com - Investing.com Canada
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) - BioSpace
Gains Report: Why is Enanta Pharmaceuticals Inc stock going upMarket Growth Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026 - businesswire.com
Enanta (NASDAQ:ENTA) Biotech Momentum Builds Across Nasdaq Index - Kalkine Media
Enanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Rodman & Renshaw - Defense World
Vanguard disaggregates holdings; reports 0 shares of Enanta (ENTA) - Stock Titan
Enanta Advances Federal Circuit Appeal in Paxlovid Patent Case - TipRanks
Federal Circuit schedules oral argument in Enanta’s patent case against Pfizer - in.investing.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Analysts at Rodman & Renshaw - MarketBeat
Federal Circuit schedules oral argument in Enanta’s patent case against Pfizer By Investing.com - za.investing.com
Aug Catalysts: Can Enanta Pharmaceuticals Inc be recession proofM&A Rumor & Entry Point Confirmation Alerts - baoquankhu1.vn
How Enanta Pharmaceuticals Inc. (ENTA) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Weekly Recap: How sensitive is Enanta Pharmaceuticals Inc to inflation2026 Movers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Trend Recap: Can Enanta Pharmaceuticals Inc sustain earnings growth2026 Technical Patterns & Smart Allocation Stock Tips - baoquankhu1.vn
ENTA SEC FilingsEnanta Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Free cash flow per share of Enanta Pharmaceuticals, Inc. – FWB:9EP - TradingView
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference - MarketBeat
Commodore Capital LP Buys New Holdings in Enanta Pharmaceuticals, Inc. $ENTA - MarketBeat
(ENTA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Enanta Shareholders Approve Board Elections and Equity Plan - The Globe and Mail
Enanta (NASDAQ: ENTA) director receives 20,000-share stock option grant - Stock Titan
Enanta (ENTA) director Lesley Russell receives stock options on 20,000 shares - Stock Titan
Enanta (ENTA) director awarded stock option for 20,000 shares - Stock Titan
Enanta (ENTA) awards 20,000 stock options to director Yujiro S. Hata - Stock Titan
Enanta (ENTA) director receives grant of 20,000 options at $14.17 - Stock Titan
Enanta (NASDAQ: ENTA) awards director 20,000-share stock option grant - Stock Titan
Enanta Pharmaceuticals presents data for KIT inhibitor EDP-978 - BioWorld MedTech
Aug Patterns: Does Enanta Pharmaceuticals Inc have strong fundamentals2026 Market WrapUp & Reliable Volume Spike Alerts - baoquankhu1.vn
Shareholders of Enanta (NASDAQ: ENTA) back equity plan expansion - Stock Titan
Enanta Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Pipeline Advances - Investing.com Canada
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Risk: Can Enanta Pharmaceuticals Inc reach all time highs this yearJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - baoquankhu1.vn
Is Enanta Pharmaceuticals Inc. stock resilient to inflationTrend Reversal & Free Expert Approved Momentum Trade Ideas - Naître et grandir
Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):